Recent News for INDP - Indaptus Therapeutics, Inc.

Date	Title
Nov 6	Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study